[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627961":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":12,"responsibleParty":31,"collaborators":12,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":12,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":12,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":12,"overallStatus":54,"whyStopped":12,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":12},{"fullName":5,"class":6},"University of Hartford","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"CGM Blind group","NO_INTERVENTION","The control group will wear the CGM for 20 days but without access to the real-time glucose data (blind mode). They will receive the data upon completion of the study.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"CGM Unblind group","EXPERIMENTAL","The CGM unblind group will wear the CGM for 20 days. They will have the real time glucose data during the study.",[18],"Behavioral: CGM Access",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"BEHAVIORAL","CGM Access","The intervention is the access to the real-time glucose via a CGM system.",[14],[26],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"Jinghui Yang, PT, MPT, PhD","CONTACT","347-429-0843","jiyang@hartford.edu",{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Jinghui Yang","Assistant Professor","100627961","continuous-glucose-monitoring-in-prediabetes-100627961",false,"NCT07455435","Continuous Glucose Monitoring in Prediabetes","Continuous Glucose Monitoring as a Tool to Promote Physical Activity in Prediabetes","Inclusion Criteria:\n\nAdults aged 18 years or older Prediabetes confirmed by the recent lab tests (within three month). If not available, it will be confirmed at lab Body mass index (BMI) \\>= 25 kg\u002Fm2 Ability to provide informed consent Ownership of a smartphone compatible with Dexcom G6 application Willing and able to comply with study procedures for 20 days\n\nExclusion Criteria:\n\nDiabetes and Glycemic Management:\n\n* Diagnosed type 1 or type 2 diabetes mellitus\n* Current use of glucose-lowering medications (metformin, sulfonylureas, GLP-1 agonists, SGLT2 inhibitors, insulin, etc.)\n* HbA1c \\>= 6.5% or fasting plasma glucose \\>= 126 mg\u002FdL\n\nCardiovascular Conditions:\n\n* History of cardiovascular disease (myocardial infarction, stroke, heart failure, coronary artery disease)\n* Peripheral artery disease\n* Uncontrolled hypertension (systolic BP \\> 160 mmHg or diastolic BP \\> 100 mmHg)\n* Raynaud phenomenon or other conditions affecting peripheral vascular assessment\n* Atrial fibrillation or other arrhythmias affecting pulse wave velocity measurement\n\nMedications Affecting Vascular Function:\n\n* Current use of vasoactive medications (nitrates, phosphodiesterase inhibitors)\n* Recent changes (\\\u003C 4 weeks) in antihypertensive medications\n* Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs)\n* Systemic corticosteroid use\n\nPhysical Activity Limitations:\n\n* Physical disability or musculoskeletal condition preventing normal ambulation\n* Use of mobility aids (wheelchair, walker, cane)\n* Medical advice to limit physical activity\n\nOther Exclusions:\n\n* Pregnancy or lactation\n* Active cancer or cancer treatment within the past 5 years (excluding non-melanoma skin cancer)\n* Chronic kidney disease (eGFR \\\u003C 60 mL\u002Fmin\u002F1.73m2)\n* Liver disease (ALT or AST \\> 3x upper limit of normal)\n* Thyroid disease (unless stable on treatment for \\> 3 months)\n* Current participation in a weight loss program or clinical trial\n* Skin conditions preventing CGM sensor placement\n* Known allergy to CGM adhesive\n* Shift work or irregular sleep schedule (may affect CGM patterns)\n* Planned travel during study period that would interfere with study visits","ALL","18 Years","65 Years",{"count":46,"type":47},50,"ESTIMATED","INTERVENTIONAL",[50],"NA","This research explores how wearable glucose monitors might help prevent type 2 diabetes in people at risk of developing the disease. Type 2 diabetes affects more than 1 in 10 Americans and costs the nation $327 billion annually. Even though it's clear that physical activity helps prevent diabetes, and that even small increases in daily movement (like walking or climbing stairs) can significantly lower risk, getting people to be more active remains challenging.\n\nA device called a continuous glucose monitor (CGM) might offer a solution. This small wearable sensor tracks blood sugar levels throughout the day and sends the information to a phone or watch. While these devices are already helping people who have diabetes manage their condition better, the investigators want to study if wearing a CGM may encourage at-risk people to become more physically active. The investigators are particularly interested in seeing whether real-time blood sugar data plus education can be an effective tool to promote lifestyle changes, such as walk more steps every day.\n\nThe study also aims to examine whether using a CGM helps stabilize blood sugar levels in prediabetes. The researchers believe that even short-term use of these monitors could lead to increased physical activity and more stable blood sugar levels, potentially helping prevent diabetes development.",[53],"Prediabetes","NOT_YET_RECRUITING","2026-03-02",{"date":57,"type":58},"2026-03-06","ACTUAL",{"date":60,"type":47},"2026-03-21",{"date":62,"type":47},"2027-05-01",{"name":5,"class":6}]